Financial Performance - Operating income for the first nine months was CNY 137,850,163.35, a 13.20% increase year-on-year[6] - Net profit attributable to shareholders decreased by 29.11% to CNY 13,227,087.20 compared to the same period last year[6] - Basic earnings per share decreased by 30.00% to CNY 0.28 compared to the same period last year[6] - The weighted average return on equity decreased by 4.80 percentage points to 6.11% compared to the same period last year[6] - Revenue grew by RMB 16.08 million, a rise of 13.20%, while gross profit margin decreased from 74.27% to 72.54%, a decline of 1.73 percentage points[14] - Net profit attributable to shareholders decreased by RMB 5.43 million, a decline of 29.11%, influenced by seasonal factors and increased operating expenses[15] - The company does not anticipate significant changes in cumulative net profit compared to the previous year, indicating stable financial performance[23] Assets and Liabilities - Total assets increased by 161.32% to CNY 698,028,694.51 compared to the end of the previous year[6] - Current assets totaled ¥545,043,909.55, compared to ¥129,936,335.92 in the previous year, representing a significant increase[28] - Non-current assets amounted to ¥152,984,784.96, an increase from ¥137,181,711.59[28] - Total liabilities were ¥72,453,847.20, compared to ¥56,680,000.99 in the previous year, reflecting an increase of about 28%[29] - Shareholders' equity reached ¥625,574,847.31, up from ¥210,438,046.52, marking a growth of approximately 197%[29] Cash Flow - Net cash flow from operating activities decreased by 96.90% to CNY 959,951.11 compared to the same period last year[6] - Cash received from operating activities increased by CNY 3.605 million, a growth of 220.93%, mainly due to an increase in research funding, project subsidies, and government grants[19] - Cash paid for purchasing goods and services rose by CNY 27.0646 million, an increase of 124.80%, primarily due to the expansion of the company's operations and increased procurement of raw materials[19] - Cash received from investment absorption increased by CNY 412.6828 million, a staggering growth of 68,780.47%, mainly due to funds raised from the IPO[19] - Cash received from borrowings increased by CNY 25 million, primarily due to a loan taken from Beijing Bank for purchasing a property[19] - The company reported a net increase in cash and cash equivalents of CNY 374,284,026.92, contrasting with a decrease of CNY -34,574,005.01 in the previous year[44] Shareholder Information - The total number of shareholders at the end of the reporting period was 10,316[9] - The largest shareholder, Lin Changqing, holds 23.55% of the shares[9] Research and Development - R&D expenses increased by RMB 6.58 million, a growth rate of 45.01%, due to expanded investment in R&D projects and an increase in the number of high-level R&D personnel[17] - Research and development expenses for Q3 2019 amounted to ¥7,702,413.33, a significant increase of 55.0% compared to ¥4,972,591.20 in Q3 2018[36] - Research and development expenses for the first three quarters of 2019 amounted to CNY 16,773,411.89, up from CNY 14,392,032.92 in the same period of 2018, indicating a 16.6% increase[39] Operating Expenses - Sales expenses rose by RMB 8.06 million, an increase of 19.73%, primarily due to increased market expansion efforts and personnel costs[16] - The company's sales expenses for Q3 2019 were ¥16,435,247.62, an increase of 13.6% from ¥14,476,392.20 in Q3 2018[36] - The sales expenses for the first three quarters of 2019 were CNY 47,977,720.08, an increase of 20.2% from CNY 39,912,648.34 in the same period of 2018[39] Other Income and Expenses - The company reported a non-operating income of CNY 2,127,830.46 for the first nine months[8] - Other income increased by RMB 3.53 million, a rise of 224.36%, mainly from various research funding and government subsidies[17] - Financial expenses increased by RMB 990,600, a growth rate of 416.70%, mainly due to interest expenses from a new loan of RMB 25 million[17]